Quick Contact : 408-458-8343
Select Page

The receipt of a FDA 483 at the conclusion of a facility inspection is a serious message to the company about the concerns the FDA has about your product quality, organizational control, complaint handling, or management oversight and the violation of the Food, Drug & Cosmetic Act. Remember, the sky is not falling but a company needs to focus on the importance of the warning and to understand the larger message the agency is sending.

Learn the most frequent deficiencies cited in FDA 483s as well as the common pitfalls when addressing compliance remediation issues. This webinar will focus on the most effective methods to draft a response and develop corrective actions, in order to successfully allay FDA concerns and avert the issuance of a Warning Letter.

Our speaker, Judith Meritz has been specializing in strategic planning and compliance mediation internationally for Life Science companies more than 30 years.

FDA inspection

Watch Webinar

Please fill the form below to access the resource.









    By submitting this form you agree that we store and process your personal data as per our Privacy Policy. We will never sell your personal information to any third party.

    Recent Webinars

    Webinars
    x
    Upcoming Webinar
    Are They Safe? Mitigating Employee Risk Factors on the Job

    Register

       April 28, 2021   |   12:00 - 01.00 PM EDT

    Is IVDR setting a new benchmark for supplier management?

    Register

       April 20, 2021   |   12:00 - 02.30 PM EDT

    Follow Us